Vertex reports first quarter 2024 financial results

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today reported consolidated financial results for the first quarter ended march 31, 2024, and reiterated full year 2024 financial guidance. “vertex delivered a strong start to 2024 with 13 percent product revenue growth and outstanding execution across the business. this quarter, we continued to expand our leadership in cf including completion of the regulatory submissions for the vanzacaftor triple, advanced the global.
VRTX Ratings Summary
VRTX Quant Ranking